Opportunity Identification

we have experience and expertise

Petri Exchange is an Investment Platform for high-value innovative biotechnologies, each of which specifically addresses the world's major diseases. We custom build every Petri Investment Vehicle to contain world-leading research and development teams. We bring confidence to investors by implementing our unique Petri Process: Originate, Engage, Capitalise and Commercialise.

Commercialisation Support

we support innovations to thrive

Petri Exchange understands the risks all investors face today, and the increasing approach for diversification. Petri Exchange develops biotechnology commercialisation opportunities that sit outside of traditional asset classes. Complementarily, Petri Exchange connects with researchers to support them through this commercialisation process. This is achieved by providing a suite of services that will ensure the research can be followed through with maximum contribution and continued engagement from researchers themselves.

We Help Advance Biotechnologies

  • Pharmaceutical
  • Medical Device
  • Medical Diagnostic
  • Gene Therapy

A New Way to Originate. Capitalise. Commercialise.


Petri Exchange is an Investment Platform for high-value innovative biotechnologies, each of which specifically addresses the world's major diseases.

We custom builds every Petri Investment Vehicle to contain world-leading research and development teams.

We bring confidence to investors by implementing our unique Petri Process: Originate, Engage, Capitalise and Commercialise.

Originate

Petri performs due diligence of select institutional IP through independent scientific, patent and market analysis.

Petri develops with seed investment, commercialisation plan development, assignment of IP, corporate structuring and exit partner engagement.

Capitalise

Approved investors are invited to invest in the equity of our portfolio biotechnology companies.

Milestone-based investment allows for a broad range of investors to come in at their preferred research stage and risk level.

Commercialise

Our portfolio biotechnology companies receive back office and ongoing fundraising support.

Investors are supported by company oversight, reporting and exit opportunity identification as the commercialisation concludes.

Upon successful completion of their commercialisation plan, each portfolio biotechnology company is exited, whether it be a pharmaceutical company, venture capital, or through an IPO.

Do you want to learn more about us?